Macquarie Group
KYNB

Macquarie Group’s Kyntra Bio KYNB Stock Holding History

Macquarie Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-186
Closed -$4.15K – 1751
2024
Q2 		$4.15K Buy
+186
New +$5.75K ﹤0.01% 1734
2022
Q4 		– Sell
-66
Closed -$34K – 1883
2022
Q3 		$34K Sell
66
-40
-38% -$12.9K ﹤0.01% 2049
2022
Q2 		$28K Hold
106
– – ﹤0.01% 2206
2022
Q1 		$32 Hold
106
– – ﹤0.01% 2278
2021
Q4 		$37K Hold
106
– – ﹤0.01% 2249
2021
Q3 		$27K Hold
106
– – ﹤0.01% 2384
2021
Q2 		$70K Hold
106
– – ﹤0.01% 2081
2021
Q1 		$92K Buy
106
+14
+15% +$14.9K ﹤0.01% 1934
2020
Q4 		$85K Hold
92
– – ﹤0.01% 1908
2020
Q3 		$95K Hold
92
– – ﹤0.01% 1796
2020
Q2 		$93K Buy
92
+15
+19% +$13.9K ﹤0.01% 1773
2020
Q1 		$67K Hold
77
– – ﹤0.01% 1754
2019
Q4 		$83K Sell
77
-67
-47% -$68.4K ﹤0.01% 1808
2019
Q3 		$133K Buy
+144
New +$158K ﹤0.01% 1688

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Macquarie Group's KYNB Position: Q3 2024 in Review

Macquarie Group sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 186 shares — an estimated $4.15K sold.

Macquarie Group first reported a position in KYNB in Q3 2019 and held it in 14 quarters. The position peaked at $133K in Q3 2019. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • Macquarie Group reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 186 Kyntra Bio shares in Q3 2024, an estimated $4.15K.
  • Macquarie Group first reported a position in Kyntra Bio in Q3 2019 and held it in 14 quarters.
  • Macquarie Group's Kyntra Bio position peaked at $133K in Q3 2019.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.